AbbVie Stock Slides on Schizophrenia Drug Study Failure
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks,
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
Shares of AbbVie Inc. ABBV dropped 0.43% to $170.35 Wednesday, on what proved to be an all-around positive trading ...
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...
Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...
Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating yesterday. David Risinger’s rating is based on several key considerations ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback